Pain and emotional well-being outcomes in Southwest Oncology Group-directed intergroup trial S0205: a phase III study comparing gemcitabine plus cetuximab versus gemcitabine as first-line therapy in patients with advanced pancreas cancer - PubMed (original) (raw)
Clinical Trial
. 2010 Aug 1;28(22):3611-6.
doi: 10.1200/JCO.2009.25.8285. Epub 2010 Jul 6.
Nancy L Vaught, Bryan Goldman, Mary W Redman, Philip A Philip, Barbara Millwood, Scott M Lippman, Thomas E Seay, Patrick J Flynn, Eileen M O'Reilly, Kendrith M Rowland, Ralph P Wong, Jacqueline Benedetti, Charles D Blanke
Affiliations
- PMID: 20606094
- PMCID: PMC2917316
- DOI: 10.1200/JCO.2009.25.8285
Clinical Trial
Pain and emotional well-being outcomes in Southwest Oncology Group-directed intergroup trial S0205: a phase III study comparing gemcitabine plus cetuximab versus gemcitabine as first-line therapy in patients with advanced pancreas cancer
Carol M Moinpour et al. J Clin Oncol. 2010.
Abstract
Purpose: S0205 was a randomized clinical trial that compared the therapeutic impact of gemcitabine versus gemcitabine plus cetuximab. Study results for patient-reported health-related quality of life (HRQL) outcomes are reported.
Patients and methods: Patients completed the Brief Pain Inventory and a measure of emotional well-being (each measured on a 0 to 10 scale) at baseline and at weeks 5, 9, 13, and 17 postrandom assignment. Worst pain status was classified as palliated (worst pain scores < 5 maintained for 2 consecutive cycles) or not palliated (remaining patients) and tested with a chi(2) test. Change in emotional well-being and worst pain (exploratory analysis) were assessed over 17 weeks using generalized estimating equations with inverse probability of censoring weights.
Results: Seven hundred twenty of 766 enrolled patients contributed baseline HRQL data. The two treatment arms did not differ statistically in the percentage of patients with successful worst pain palliation. Longitudinal analyses showed significantly improved emotional well-being for patients on both arms by weeks 13 and 17 (P < .01 and P < .001). An exploratory longitudinal analysis of worst pain showed significant decreases at all time points for both arms (P < .01 and P < .001). Significant treatment arm differences for either worst pain or emotional well-being were not observed at any of the assessment times.
Conclusion: We observed palliated pain and improved well-being for patients on this trial. However, these improvements were similar in both treatment arms, suggesting that the addition of cetuximab did not contribute to improvement in these HRQL outcomes.
Conflict of interest statement
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.
Figures
Fig 1.
CONSORT diagram for S0205 clinical and health-related quality of life (HRQL) samples. (*) Denominators give total number of eligible patients; numerators give number of eligible patients with baseline HRQL data.
Similar articles
- Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205.
Philip PA, Benedetti J, Corless CL, Wong R, O'Reilly EM, Flynn PJ, Rowland KM, Atkins JN, Mirtsching BC, Rivkin SE, Khorana AA, Goldman B, Fenoglio-Preiser CM, Abbruzzese JL, Blanke CD. Philip PA, et al. J Clin Oncol. 2010 Aug 1;28(22):3605-10. doi: 10.1200/JCO.2009.25.7550. Epub 2010 Jul 6. J Clin Oncol. 2010. PMID: 20606093 Free PMC article. Clinical Trial. - A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma.
Ko AH, Youssoufian H, Gurtler J, Dicke K, Kayaleh O, Lenz HJ, Keaton M, Katz T, Ballal S, Rowinsky EK. Ko AH, et al. Invest New Drugs. 2012 Aug;30(4):1597-606. doi: 10.1007/s10637-011-9691-8. Epub 2011 Jun 1. Invest New Drugs. 2012. PMID: 21629990 Clinical Trial. - Randomized phase II--study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer--PARC: study protocol [ISRCTN56652283].
Krempien R, Muenter MW, Huber PE, Nill S, Friess H, Timke C, Didinger B, Buechler P, Heeger S, Herfarth KK, Abdollahi A, Buchler MW, Debus J. Krempien R, et al. BMC Cancer. 2005 Oct 11;5:131. doi: 10.1186/1471-2407-5-131. BMC Cancer. 2005. PMID: 16219105 Free PMC article. Clinical Trial. - Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy.
Rivera F, López-Tarruella S, Vega-Villegas ME, Salcedo M. Rivera F, et al. Cancer Treat Rev. 2009 Jun;35(4):335-9. doi: 10.1016/j.ctrv.2008.11.007. Epub 2009 Jan 7. Cancer Treat Rev. 2009. PMID: 19131170 Review. - Gemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer: a meta-analysis of randomized phase III trials.
Ottaiano A, Capozzi M, De Divitiis C, De Stefano A, Botti G, Avallone A, Tafuto S. Ottaiano A, et al. Acta Oncol. 2017 Mar;56(3):377-383. doi: 10.1080/0284186X.2017.1288922. Epub 2017 Feb 17. Acta Oncol. 2017. PMID: 28256961 Review.
Cited by
- Evaluating Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology: A Systematic Review and Quantitative Analysis.
Kovic B, Jin X, Kennedy SA, Hylands M, Pedziwiatr M, Kuriyama A, Gomaa H, Lee Y, Katsura M, Tada M, Hong BY, Cho SM, Hong PJ, Yu AM, Sivji Y, Toma A, Xie L, Tsoi L, Waligora M, Prasad M, Bhatnagar N, Thabane L, Brundage M, Guyatt G, Xie F. Kovic B, et al. JAMA Intern Med. 2018 Dec 1;178(12):1586-1596. doi: 10.1001/jamainternmed.2018.4710. JAMA Intern Med. 2018. PMID: 30285081 Free PMC article. - Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
Sohal DP, Mangu PB, Khorana AA, Shah MA, Philip PA, O'Reilly EM, Uronis HE, Ramanathan RK, Crane CH, Engebretson A, Ruggiero JT, Copur MS, Lau M, Urba S, Laheru D. Sohal DP, et al. J Clin Oncol. 2016 Aug 10;34(23):2784-96. doi: 10.1200/JCO.2016.67.1412. Epub 2016 May 31. J Clin Oncol. 2016. PMID: 27247222 Free PMC article. Review. - Quality of life, long-term survivors and long-term outcome from the ABC-02 study.
Bridgewater J, Lopes A, Palmer D, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Valle J, Wasan H. Bridgewater J, et al. Br J Cancer. 2016 Apr 26;114(9):965-71. doi: 10.1038/bjc.2016.64. Br J Cancer. 2016. PMID: 27115567 Free PMC article. - Systemic therapy in stage IV pancreatic cancer: a population-based analysis using the National Cancer Data Base.
Khanal N, Upadhyay S, Dahal S, Bhatt VR, Silberstein PT. Khanal N, et al. Ther Adv Med Oncol. 2015 Jul;7(4):198-205. doi: 10.1177/1758834015579313. Ther Adv Med Oncol. 2015. PMID: 26136851 Free PMC article. - Sequential FOLFIRI.3 + Gemcitabine Improves Health-Related Quality of Life Deterioration-Free Survival of Patients with Metastatic Pancreatic Adenocarcinoma: A Randomized Phase II Trial.
Anota A, Mouillet G, Trouilloud I, Dupont-Gossart AC, Artru P, Lecomte T, Zaanan A, Gauthier M, Fein F, Dubreuil O, Paget-Bailly S, Taieb J, Bonnetain F. Anota A, et al. PLoS One. 2015 May 26;10(5):e0125350. doi: 10.1371/journal.pone.0125350. eCollection 2015. PLoS One. 2015. PMID: 26010884 Free PMC article. Clinical Trial.
References
- Jacobson JS. Quality and quantity of life with pancreatic cancer. Digestion. 2006;74:116–117. - PubMed
- Greenwald HP, Bonica JJ, Bergner M. The prevalence of pain in four cancers. Cancer. 1987;60:2563–2569. - PubMed
- Fasanella KE, Davis B, Lyons J, et al. Pain in chronic pancreatitis and pancreatic cancer. Gastroenterol Clin North Am. 2007;36:335–364. ix. - PubMed
- Kelsen DP, Portenoy RK, Thaler HT, et al. Pain and depression in patients with newly diagnosed pancreas cancer. J Clin Oncol. 1995;13:748–755. - PubMed
- Schmier J, Elixhauser A, Halpern MT. Health-related quality of life evaluations of gastric and pancreatic cancer. Hepatogastroenterology. 1999;46:1998–2004. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- CA33601/CA/NCI NIH HHS/United States
- N01 CA032102/CA/NCI NIH HHS/United States
- U10 CA077202/CA/NCI NIH HHS/United States
- U10 CA033601/CA/NCI NIH HHS/United States
- U10 CA035195/CA/NCI NIH HHS/United States
- CA35195/CA/NCI NIH HHS/United States
- U10 CA032102/CA/NCI NIH HHS/United States
- U10 CA077651/CA/NCI NIH HHS/United States
- N01 CA038926/CA/NCI NIH HHS/United States
- CA77202/CA/NCI NIH HHS/United States
- U10 CA038926/CA/NCI NIH HHS/United States
- CA25224/CA/NCI NIH HHS/United States
- CA31946/CA/NCI NIH HHS/United States
- U10 CA021115/CA/NCI NIH HHS/United States
- U10 CA031946/CA/NCI NIH HHS/United States
- CA77651/CA/NCI NIH HHS/United States
- CA21115/CA/NCI NIH HHS/United States
- U10 CA025224/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical